Vaxart Inc
VXRT0.320USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
73.03MMarket Cap
LossP/E TTM
More Details of Vaxart Inc Company
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
Vaxart Inc Info
Ticker SymbolVXRT
Company nameVaxart Inc
IPO dateMar 17, 1980
CEOMr. Steven (Steve) Lo
Number of employees105
Security typeOrdinary Share
Fiscal year-endMar 17
Address170 Harbor Way, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code94080
Phone16505503500
Websitehttps://vaxart.com/
Ticker SymbolVXRT
IPO dateMar 17, 1980
CEOMr. Steven (Steve) Lo
Company Executives of Vaxart Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Edward B. Berg
Mr. Edward B. Berg
Senior Vice President, General Counsel
Senior Vice President, General Counsel
435.74K
+1053.17%
Mr. Jeroen Grasman
Mr. Jeroen Grasman
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
350.00K
--
Mr. Steven (Steve) Lo
Mr. Steven (Steve) Lo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.34K
+69.36%
Dr. Elaine J. Heron, Ph.D.
Dr. Elaine J. Heron, Ph.D.
Independent Director
Independent Director
80.57K
+98.60%
Dr. Sean N. Tucker, Ph.D.
Dr. Sean N. Tucker, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Mr. W. Mark Watson
Mr. W. Mark Watson
Lead Independent Director
Lead Independent Director
--
--
Dr. James F. Cummings, M.D.
Dr. James F. Cummings, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kevin P. Finney
Mr. Kevin P. Finney
Independent Director
Independent Director
--
--
Mr. Matt Stein
Mr. Matt Stein
IR Contact Officer
IR Contact Officer
--
--
Ms. Laurie Hastings
Ms. Laurie Hastings
Senior Vice President of Human Resources
Senior Vice President of Human Resources
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Edward B. Berg
Mr. Edward B. Berg
Senior Vice President, General Counsel
Senior Vice President, General Counsel
435.74K
+1053.17%
Mr. Jeroen Grasman
Mr. Jeroen Grasman
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
350.00K
--
Mr. Steven (Steve) Lo
Mr. Steven (Steve) Lo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.34K
+69.36%
Dr. Elaine J. Heron, Ph.D.
Dr. Elaine J. Heron, Ph.D.
Independent Director
Independent Director
80.57K
+98.60%
Dr. Sean N. Tucker, Ph.D.
Dr. Sean N. Tucker, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Mr. W. Mark Watson
Mr. W. Mark Watson
Lead Independent Director
Lead Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Marshall Wace LLP
0.81%
Finney (Michael Joseph)
0.29%
Lee (Phillip E.)
0.26%
Berg (Edward B)
0.18%
Grasman (Jeroen Nicolaas)
0.15%
Other
98.31%
Shareholders
Shareholders
Proportion
Marshall Wace LLP
0.81%
Finney (Michael Joseph)
0.29%
Lee (Phillip E.)
0.26%
Berg (Edward B)
0.18%
Grasman (Jeroen Nicolaas)
0.15%
Other
98.31%
Shareholder Types
Shareholders
Proportion
Individual Investor
1.44%
Investment Advisor/Hedge Fund
0.82%
Investment Advisor
0.13%
Venture Capital
0.04%
Family Office
0.02%
Other
97.55%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
199
11.92M
4.96%
-39.01M
2025Q2
223
30.23M
13.21%
-34.48M
2025Q1
260
32.73M
14.34%
-33.64M
2024Q4
273
38.15M
16.82%
-29.38M
2024Q3
304
39.77M
17.54%
-31.47M
2024Q2
307
43.16M
19.03%
-9.14M
2024Q1
311
42.29M
24.34%
-1.37M
2023Q4
307
17.70M
11.60%
-12.17M
2023Q3
319
19.94M
13.09%
-20.38M
2023Q2
329
30.49M
20.10%
-12.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Marshall Wace LLP
1.76M
0.77%
+1.76M
--
Jun 30, 2025
Finney (Michael Joseph)
686.84K
0.3%
-16.00K
-2.28%
Jul 29, 2025
Lee (Phillip E.)
631.62K
0.28%
+397.95K
+170.31%
Mar 24, 2025
Berg (Edward B)
435.74K
0.19%
+397.95K
+1053.17%
Mar 24, 2025
Grasman (Jeroen Nicolaas)
350.00K
0.15%
+350.00K
--
May 19, 2025
Tucker (Sean N.)
271.58K
0.12%
-3.91K
-1.42%
Jul 29, 2025
Cummings (James F.)
257.83K
0.11%
+38.22K
+17.40%
Jul 29, 2025
Floroiu (Cezar Andrei)
207.61K
0.09%
--
--
Jul 29, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco RAFI US 1500 Small-Mid ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Vaxart Inc?
The top five shareholders of Vaxart Inc are:
Marshall Wace LLP holds 1.76M shares, accounting for 0.77% of the total shares.
Finney (Michael Joseph) holds 686.84K shares, accounting for 0.30% of the total shares.
Lee (Phillip E.) holds 631.62K shares, accounting for 0.28% of the total shares.
Berg (Edward B) holds 435.74K shares, accounting for 0.19% of the total shares.
Grasman (Jeroen Nicolaas) holds 350.00K shares, accounting for 0.15% of the total shares.
Marshall Wace LLP holds 1.76M shares, accounting for 0.77% of the total shares.
Finney (Michael Joseph) holds 686.84K shares, accounting for 0.30% of the total shares.
Lee (Phillip E.) holds 631.62K shares, accounting for 0.28% of the total shares.
Berg (Edward B) holds 435.74K shares, accounting for 0.19% of the total shares.
Grasman (Jeroen Nicolaas) holds 350.00K shares, accounting for 0.15% of the total shares.
What are the top three shareholder types of Vaxart Inc?
The top three shareholder types of Vaxart Inc are:
Marshall Wace LLP
Finney (Michael Joseph)
Lee (Phillip E.)
Marshall Wace LLP
Finney (Michael Joseph)
Lee (Phillip E.)
How many institutions hold shares of Vaxart Inc (VXRT)?
As of 2025Q3, 199 institutions hold shares of Vaxart Inc, with a combined market value of approximately 11.92M, accounting for 4.96% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.24%.
What is the biggest source of revenue for Vaxart Inc?
In --, the -- business generated the highest revenue for Vaxart Inc, amounting to -- and accounting for --% of total revenue.
